Literature DB >> 28376239

Clinical Characteristics, Disease Activity, and Patient-Reported Outcomes in Psoriatic Arthritis Patients With Dactylitis or Enthesitis: Results From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry.

Philip J Mease1, Chitra Karki2, Jacqueline B Palmer3, Carol J Etzel4, Arthur Kavanaugh5, Christopher T Ritchlin6, Wendi Malley2, Vivian Herrera3, Melody Tran7, Jeffrey D Greenberg8.   

Abstract

OBJECTIVE: To characterize psoriatic arthritis (PsA) patients with dactylitis or enthesitis and evaluate the associations of these manifestations with disease activity and patient-reported outcomes.
METHODS: Using the Corrona PsA/Spondyloarthritis Registry, patient characteristics, disease activity, and patient-reported outcomes at registry enrollment were assessed for PsA patients ages ≥18 years with or without dactylitis or enthesitis. Regression models were used to evaluate associations of dactylitis and enthesitis with outcomes, including minimal disease activity, Health Assessment Questionnaire scores, patient-reported pain and fatigue, and work productivity (Work Productivity and Activity Impairment questionnaire). Adjustments were made for age, sex, race, body mass index, disease duration, and history of biologic agent, disease-modifying antirheumatic drug, and prednisone use.
RESULTS: This analysis included 1,567 PsA patients (420 with enthesitis; 228 with dactylitis). Patients with versus without dactylitis or enthesitis had greater disease activity and were less likely to be in minimal disease activity (P < 0.05). Patients with versus without enthesitis had poorer functional status as assessed by the Health Assessment Questionnaire (adjusted P = 4.15 x 10-5 ), greater patient-reported pain and fatigue (adjusted P < 0.0001), and greater likelihood of any impairment while working (adjusted odds ratio [OR] 1.57, P = 0.027), overall work impairment (OR 1.85, P = 0.006), and activity impairment (OR 1.77, P = 0.008). Dactylitis was associated with similar numerical trends, but differences versus patients without dactylitis did not reach statistical significance.
CONCLUSION: Enthesitis and dactylitis are associated with greater overall disease burden of PsA, underscoring the importance of identifying, assessing, and effectively managing these periarticular manifestations.
© 2017, American College of Rheumatology.

Entities:  

Mesh:

Year:  2017        PMID: 28376239     DOI: 10.1002/acr.23249

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  18 in total

1.  Innovations in Psoriasis Management: Based on Selected Presentations from the Symposium for Cosmetic Advances & Laser Education (SCALE) Virtual Congress-July 24 to 26, 2020.

Authors:  Jo Ann Lequang
Journal:  J Clin Aesthet Dermatol       Date:  2020-11-01

Review 2.  Current concepts and unmet needs in psoriatic arthritis.

Authors:  Farrouq Mahmood; Laura C Coates; Philip S Helliwell
Journal:  Clin Rheumatol       Date:  2017-11-13       Impact factor: 2.980

3.  Enthesitis and its relationship with disease activity, functional status, and quality of life in psoriatic arthritis: a multi-center study.

Authors:  Ismihan Sunar; Sebnem Ataman; Kemal Nas; Erkan Kilic; Betul Sargin; Sevtap Acer Kasman; Hakan Alkan; Nilay Sahin; Gizem Cengiz; Nihan Cuzdan; Ilknur Albayrak Gezer; Dilek Keskin; Cevriye Mülkoğlu; Hatice Resorlu; Ajda Bal; Mehmet Tuncay Duruöz; Okan Küçükakkaş; Ozan Volkan Yurdakul; Meltem Alkan Melikoglu; Yıldıray Aydın; F Figen Ayhan; Hatice Bodur; Mustafa Calis; Erhan Capkın; Gul Devrimsel; Kevser Gok; Sami Hizmetli; Ayhan Kamanlı; Yaşar Keskin; Hilal Kocabas; Oznur Kutluk; Nesrin Şen; Omer Faruk Şendur; Ibrahim Tekeoğlu; Sena Tolu; Murat Toprak; Tiraje Tuncer
Journal:  Rheumatol Int       Date:  2019-11-26       Impact factor: 2.631

4.  Determinants of Patient-Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association With Sex in 458 Patients From Fourteen Countries.

Authors:  Ana-Maria Orbai; Jamie Perin; Clémence Gorlier; Laura C Coates; Uta Kiltz; Ying Ying Leung; Penelope E Palominos; Juan D Cañete; Rossana Scrivo; Andra Balanescu; Emmanuelle Dernis; Sandra Tälli; Adeline Ruyssen-Witrand; Martin Soubrier; Sibel Aydin; Lihi Eder; Inna Gaydukova; Ennio Lubrano; Umut Kalyoncu; Pascal Richette; M Elaine Husni; Josef S Smolen; Maarten de Wit; Laure Gossec
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-12       Impact factor: 4.794

Review 5.  Enthesitis and Dactylitis in Psoriatic Disease: A Guide for Dermatologists.

Authors:  Jerry Bagel; Sergio Schwartzman
Journal:  Am J Clin Dermatol       Date:  2018-12       Impact factor: 7.403

6.  Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies.

Authors:  Peter Nash; Laura C Coates; Roy Fleischmann; Kim A Papp; Juan Jesus Gomez-Reino; Keith S Kanik; Cunshan Wang; Joseph Wu; Sujatha Menon; Thijs Hendrikx; William C Ports
Journal:  Rheumatol Ther       Date:  2018-11-09

Review 7.  A paradigm shift in studies based on rheumatoid arthritis clinical registries.

Authors:  Soo-Kyung Cho; Yoon-Kyoung Sung
Journal:  Korean J Intern Med       Date:  2019-02-18       Impact factor: 2.884

8.  Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis.

Authors:  Dafna D Gladman; Ana-Maria Orbai; Uta Klitz; James Cheng-Chung Wei; Gaia Gallo; Julie Birt; Suchitrita Rathmann; David Shrom; Helena Marzo-Ortega
Journal:  Arthritis Res Ther       Date:  2019-01-29       Impact factor: 5.156

9.  Management of Psoriatic Arthritis: Turkish League Against Rheumatism (TLAR) Expert Opinions.

Authors:  Kemal Nas; Erkan Kiliç; Remzi Çevik; Hatice Bodur; Şebnem Ataman; Figen Ayhan; Özgür Akgül; Ayşen Akinci; Zuhal Altay; Erhan Çapkın; Abdullah Zübeyir Dağli; Tuncay Duruöz; Gülcan Gürer; Feride Göğüş; Yeşim Garip; Cahit Kaçar; Ayhan Kamanli; Ece Kaptanoğlu; Taciser Kaya; Hilal Kocabaş; Erhan Ali Özdemirel; Sumru Özel; İlhan Sezer; İsmihan Sunar; Gürkan Yilmaz
Journal:  Arch Rheumatol       Date:  2018-05-21       Impact factor: 1.472

10.  Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2.

Authors:  Iain B McInnes; Soumya D Chakravarty; Isabel Apaolaza; Shelly Kafka; Elizabeth C Hsia; Yin You; Arthur Kavanaugh
Journal:  RMD Open       Date:  2019-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.